Structure Therapeutics Inc. (GPCR) - Dilution Analysis

8-K filing: Structure Therapeutics, Inc. entered into an underwriting agreement to issue and sell 8,461,538 American Depositary Shares (ADSs) at $65.00 per ADS and pre-funded warrants to purchase 1,538,462 ADSs at $64.9999 per warrant, with gross proceeds of approximately $650.0 million. ($650.0M proceeds)

10-Q filing | 175.5M shares outstanding

10-Q filing | 172.6M shares outstanding

10-Q filing | 172.1M shares outstanding

10-K filing | 157.9M shares outstanding

10-Q filing | 171.6M shares outstanding

10-Q filing | 171.6M shares outstanding

S-1 filing: The filing is for an offering of 8,000,000 American Depositary Shares, representing 24,000,000 ordinary shares, and pre-funded warrants to purchase ordinary shares, represented by ADSs.

10-Q filing | 139.7M shares outstanding

10-K filing | 139.2M shares outstanding

10-Q filing | 114.9M shares outstanding

S-1 filing: The filing is an S-1 form for the resale of up to 24,019,215 ordinary shares by selling shareholders, with the company not receiving any proceeds from the sale.

8-K filing: Structure Therapeutics Inc. entered into a share purchase agreement to sell and issue 21,617,295 ordinary shares and 2,401,920 non-voting ordinary shares in a private placement for gross proceeds of approximately $300 million, with the proceeds to be used to advance the development of the Company's oral small molecule GLP-1R agonist, GSBR-1290, and for working capital and other general corporate purposes. ($300.0M proceeds)

10-Q filing | 114.8M shares outstanding

10-Q filing | 114.7M shares outstanding

S-1/A filing: This S-1/A filing relates to a proposed offering of American Depositary Shares (ADSs) representing ordinary shares of Structure Therapeutics Inc.